Eller, Urs v Cheong Kiat Wah [2021] SGHC 253

Case Details

• Citation: [2021] SGHC 253
• Court: General Division of the High Court of the Republic of Singapore
• Decision Date: 10 November 2021
• Coram: Philip Jeyaretnam J
• Case Number: Suit No 176 of 2019
• Hearing Date(s): 24–26 August, 24 September 2021
• Claimants / Plaintiffs: Urs Eller
• Respondent / Defendant: Cheong Kiat Wah
• Counsel for Claimants: Cai Enhuai Amos, Tian Keyun, Yong Ying Jie (Yuen Law LLC)
• Counsel for Respondent: Pang Khin Wee (Peng Qinwei) (Hoh Law Corporation)
• Practice Areas: Trusts; Breach of trust; Remedies; Evidence

Summary

The decision in Eller, Urs v Cheong Kiat Wah [2021] SGHC 253 represents a significant clarification of the principles governing equitable compensation for a breach of trust involving the dilution of shareholding interests. This judgment followed a prior liability trial where it was established that the defendant, acting as an express trustee for the plaintiff, breached his fiduciary duties by unilaterally increasing the share capital of a company, thereby diluting the plaintiff’s beneficial interest from 50% to a negligible 0.0143%. The primary focus of this subsequent proceeding was the assessment of quantum—specifically, how to measure the financial loss suffered by a beneficiary when a trustee misuses voting rights to entrench their own control and diminish the beneficiary's stake.

The court adopted a reparative approach to equitable compensation, rejecting more punitive or formulaic models of damages. Philip Jeyaretnam J held that the proper measure of loss is the difference between the value the plaintiff’s shareholding would have had if the breach had not occurred ("Value A") and the actual current value of that diluted shareholding ("Value B"). This "Value A minus Value B" framework requires a rigorous counterfactual analysis: the court must determine what the company’s performance and value would have been had the unauthorized share issuance never taken place. This involves assessing whether the company could have secured necessary capital or achieved its sales targets without the breach-induced capital injection.

A critical doctrinal contribution of this case is the court's treatment of corporate voting rights as trust property. By applying the English Court of Appeal's decision in Butt v Kelson [1952] 1 Ch 197, the court affirmed that a trustee holding shares is bound to exercise the attached voting rights in accordance with the beneficiary's instructions. The unauthorized exercise of these rights to issue shares to the trustee is, in substance, the trustee treating trust property as his own. This characterization bridges the gap between company law mechanisms and trust law remedies, ensuring that the equitable protection of a beneficiary’s interest remains robust even within a corporate structure.

Ultimately, the court awarded the plaintiff RM 3,032,233.25 in equitable compensation. The judgment serves as a cautionary tale for nominee shareholders and a roadmap for practitioners navigating the complexities of valuation in trust litigation. It underscores that while valuation is "not a science" but an "opinion based on analysis," the court will demand a sound methodological basis, preferring experts who provide logical, supported evidence over those whose testimony is deemed "illogical and unsupported."

Timeline of Events

1. 19 September 2014: The defendant registered Swiss Medicare Sdn Bhd (the "Company") in Malaysia.
2. 29 November 2014: The parties executed a loan agreement for the sum of RM 350,000, intended as start-up capital for the Company.
3. 30 November 2014: The parties executed the Trust Deed, under which the defendant held 50 shares as express trustee for the plaintiff.
4. 15 January 2015: The defendant caused the Company to allot an additional 350,000 shares to himself through an ordinary resolution (the "Share Issuance"), without the plaintiff's consent.
5. 15 September 2016: A key date in the subsequent factual dispute regarding the Company's operational timeline and sales growth.
6. 13 September 2019: Commencement of legal proceedings via Suit No 176 of 2019.
7. 2020: The Liability Trial concluded with the judgment in [2020] SGHC 106, finding the defendant liable for breach of trust but reserving quantum for separate assessment.
8. 21 January 2021: The plaintiff's expert, Mr. Aditya Gupta, issued his valuation report.
9. 24–26 August 2021: Substantive hearing for the assessment of quantum.
10. 24 September 2021: Final hearing date for the quantum proceedings.
11. 10 November 2021: Delivery of the judgment in [2021] SGHC 253.

What Were the Facts of This Case?

The dispute centered on Swiss Medicare Sdn Bhd, a Malaysian company incorporated on 19 September 2014 for the purpose of distributing hearing aids. The plaintiff, Urs Eller, and the defendant, Cheong Kiat Wah, entered into a business arrangement where the plaintiff provided the initial financial backing. On 29 November 2014, the plaintiff lent the defendant RM 350,000 in his personal capacity, with the mutual understanding that these funds would be used to further the Company’s business. This loan was formalized in a Loan Agreement.

Parallel to the loan, the parties executed a Trust Deed on 30 November 2014. Under this deed, the defendant held 50 shares of the Company as an express trustee for the plaintiff. At the time of incorporation, the Company had a total of 100 issued shares. Thus, the plaintiff’s beneficial interest in these 50 shares represented a 50% stake in the Company. The Trust Deed contained specific protections for the plaintiff, notably Clauses 3.3 and 3.4(b), which designated certain actions as "Reserved Matters." These matters required the defendant to exercise the voting rights attached to the trust shares only in accordance with the plaintiff’s instructions. Crucially, any increase in the Company’s issued share capital was a Reserved Matter.

Despite these clear contractual and fiduciary obligations, the defendant acted unilaterally. On 15 January 2015, less than two months after the Trust Deed was signed, the defendant caused the Company to pass an ordinary resolution allotting an additional 350,000 shares to himself. This "Share Issuance" was performed without the plaintiff’s knowledge or consent. The immediate effect was a massive dilution of the plaintiff’s interest. While he still beneficially owned 50 shares, the total number of issued shares had jumped from 100 to 350,100. Consequently, the plaintiff’s 50% stake was reduced to approximately 0.0143%.

The defendant’s justification for this move was that the Company required a higher paid-up capital to satisfy regulatory or commercial requirements in Malaysia, specifically to obtain necessary licenses for hearing aid distribution. He argued that the RM 350,000 loan from the plaintiff was converted into equity through this issuance. However, the liability trial judge in [2020] SGHC 106 had already rejected these defenses, finding that the defendant had breached his duties as a trustee by failing to seek the plaintiff's direction on a Reserved Matter and by using the trust property (the voting rights) for his own benefit.

The quantum trial, therefore, had to grapple with the financial consequences of this dilution. The plaintiff contended that he was entitled to the value of a 50% stake in a company that had grown significantly since 2015. The defendant countered that the Company’s success was entirely due to the capital injection and his own efforts, and that without the Share Issuance, the Company would have failed or remained a shell. The evidence record included conflicting expert reports from Mr. Aditya Gupta (for the plaintiff) and Mr. Arul Gunendran (for the defendant), as well as issues regarding the admissibility of statements from a Malaysian witness, Mr. Woo, who refused to attend the trial to be cross-examined.

The Company’s financial performance was a central exhibit. By the time of the valuation date (31 October 2020), the Company had achieved substantial sales. The court had to determine whether these sales levels were a direct result of the breach (the Share Issuance) or whether they could have been achieved regardless. This required a deep dive into the Company's business model, its relationships with hospitals and medical centers, and the necessity of the RM 350,000 capital for its operations.

What Were the Key Legal Issues?

The court identified three primary issues to be determined in the assessment of quantum:

• Issue 1: The Nature of the Beneficial Interest: Whether the plaintiff and defendant both intended that the plaintiff should be a 50% shareholder in the Company, or merely a holder of 50 shares regardless of the total capital. This involved interpreting the Trust Deed and the parties' mutual understandings at the time of incorporation.
• Issue 2: The Counterfactual Sales Level: Whether, if not for the Share Issuance, the Company would have achieved its current level of sales. This was the "but for" test of causation in equity, requiring the court to decide if the Company's growth was inextricably linked to the unauthorized capital increase.
• Issue 3: Determination of Value A and Value B: The calculation of the specific financial figures required for the reparative formula. Value A represented the value of the plaintiff's 50% stake in the counterfactual scenario (no breach), while Value B represented the actual value of his diluted 0.0143% stake at the valuation date.
• Evidential Issue: Admissibility of Hearsay: Whether the statement of Mr. Woo, a Malaysian witness who refused to testify, was admissible under Section 32(1)(j)(iv) of the Evidence Act.

How Did the Court Analyse the Issues?

The court’s analysis began with a foundational premise regarding the nature of the breach. Philip Jeyaretnam J emphasized that the unauthorized exercise of voting rights by a trustee is a serious transgression:

"The unauthorised exercise by a trustee of voting rights attached to shares held on trust for a beneficiary in order to cause the company to issue shares to the trustee with the immediate intended result of turning the trustee into the majority owner is in substance the trustee treating the trust property as his own." (at [19])

Issue 1: Plaintiff as 50% Shareholder

The court first addressed whether the plaintiff was intended to be a 50% shareholder. The defendant argued that the trust was only over "50 shares" and that there was no agreement that this would always constitute 50% of the Company. The court rejected this narrow interpretation. It found that at the time of the Trust Deed, the total issued shares were 100. The parties’ commercial intent, backed by the "Reserved Matters" clauses, was to maintain an equal partnership. The court held that the plaintiff’s right to give instructions on any increase in share capital was designed precisely to protect his 50% proportion. Therefore, for the purpose of calculating Value A, the plaintiff was treated as a 50% shareholder.

Issue 2: Counterfactual Sales Levels

The defendant’s primary defense against a high quantum award was that the Company’s sales growth was dependent on the Share Issuance. He argued that without the RM 350,000 being reflected as paid-up capital, the Company could not have secured the necessary licenses or the trust of Malaysian hospitals. The court, however, found this argument unpersuasive. The evidence showed that the RM 350,000 had already been provided by the plaintiff as a loan. The Company had the cash; the breach was merely the form in which that cash was accounted for (equity vs. debt). The court concluded that the Company would have achieved the same level of sales even if the RM 350,000 had remained a loan or if the shares had been issued proportionally to both parties. The "but for" cause of the Company's success was the availability of the funds and the defendant's management, not the specific act of diluting the plaintiff.

Issue 3: Determination of Value A and Value B

This issue required a detailed evaluation of expert testimony. The court was faced with two starkly different approaches:

• Mr. Gupta (Plaintiff's Expert): He used the Guideline Public Company (GPC) method and the Discounted Cash Flow (DCF) method. He valued the Company as a going concern as of 31 October 2020. He calculated the Company's value at RM 6,066,118.
• Mr. Arul (Defendant's Expert): His evidence was summarily rejected by the court. The judge noted: "Turning to Mr Arul’s evidence first, I derived no assistance from it at all. His evidence was illogical and unsupported." (at [54]). Mr. Arul had attempted to argue that the shares had no value or that the value should be based on the net asset value, which ignored the Company's significant earnings.

The court accepted Mr. Gupta’s methodology as "sound in principle." However, the court made a crucial adjustment. Mr. Gupta had applied a "Lack of Marketability Discount" (DLOM) of 30% to Value A but not to Value B. The court found this inconsistent. If the plaintiff had remained a 50% shareholder (Value A), he would have had significant control and a more marketable stake than a 0.0143% minority holder (Value B). The court decided that no DLOM should be applied to Value A, as it represented a joint-control stake in a private company where the two owners were the only directors. For Value B, the court applied a 10% discount to reflect the extreme minority position.

The Application of Butt v Kelson

A pivotal part of the legal reasoning involved the application of Butt v Kelson [1952] 1 Ch 197. The court cited Romer LJ at 207 for the principle that:

"…the beneficiaries are entitled to be treated as though they were the registered shareholders in respect of trust shares… and can compel the trustee directors if necessary to use their votes as the beneficiaries… think proper…" (at [42])

This authority supported the court's finding that the defendant’s failure to follow the plaintiff's instructions on the Share Issuance was not just a contractual breach of the Trust Deed but a fundamental breach of trust. The voting rights were not the defendant's to use as he pleased; they were held for the plaintiff's benefit.

Evidential Admissibility (Section 32)

The defendant sought to rely on a statement by a Mr. Woo, a Malaysian citizen who was competent but refused to give evidence in Singapore. The defendant invoked Section 32(1)(j)(iv) of the Evidence Act (Cap 97, 1997 Rev Ed), which allows hearsay statements if the person refuses to give evidence. The court accepted the statement was admissible but gave it "little weight" because it could not be tested by cross-examination. This highlights the court's preference for direct, testable evidence in complex quantum assessments.

What Was the Outcome?

The court calculated the equitable compensation by determining the two key variables:

• Value A: 50% of the Company's value (RM 6,066,118) without any marketability discount. This amounted to RM 3,033,059.
• Value B: 0.0143% of the Company's adjusted value (RM 6,416,118, which included the RM 350,000 capital) with a 90% discount (representing the 10% value remaining after a 90% DLOM/minority discount). This resulted in a negligible RM 825.75.

The difference between these two values represented the plaintiff's loss. The court's final order was as follows:

"I award the plaintiff equitable compensation in the sum of RM 3,032,233.25." (at [71])

The court also addressed the following ancillary matters:

• Currency: The award was made in Malaysian Ringgit (MYR), reflecting the jurisdiction of the Company and the currency of the original investment and losses.
• Costs and Interest: The judge did not make an immediate order on costs or interest, stating: "I will hear parties on interest and costs." (at [71]).
• Disposition: The defendant was ordered to pay the plaintiff the sum of RM 3,032,233.25 as compensatory relief for the breach of trust.

Why Does This Case Matter?

Eller, Urs v Cheong Kiat Wah is a landmark decision for several reasons, primarily concerning the intersection of trust law and corporate governance in Singapore. For practitioners, its significance lies in three main areas: the methodology of equitable compensation, the status of voting rights, and the judicial approach to expert valuation.

Firstly, the case provides a clear judicial endorsement of the reparative model of equitable compensation in the context of share dilution. By focusing on the "Value A minus Value B" formula, the court moved away from potential confusion between "falsification" (a substitutive remedy) and "compensation" (a reparative remedy). This distinction is vital. Falsification treats the unauthorized transaction as if it never happened, often requiring the trustee to restore the specific property. Compensation, as applied here, acknowledges the breach has occurred and seeks to make the beneficiary whole financially. This is particularly practical in corporate settings where reversing a share issuance years later might be commercially impossible or disruptive to third parties.

Secondly, the judgment reinforces the sanctity of the beneficiary's control over trust property, even when that property consists of intangible rights like votes. By applying Butt v Kelson, the court sent a clear message to nominee directors and shareholders: you are not "owners" in the eyes of equity. The use of voting power to entrench one's own position at the expense of a beneficiary is a classic breach of the "no-conflict" and "no-profit" rules. This case serves as a primary authority for the proposition that a trustee’s misuse of voting rights to dilute a beneficiary is equivalent to the trustee "treating the trust property as his own."

Thirdly, the case offers a masterclass in judicial scrutiny of expert evidence. Philip Jeyaretnam J’s blunt rejection of the defendant’s expert highlights that the court will not be swayed by experts who fail to provide a logical nexus between their methodology and the facts. The court's willingness to "tweak" the accepted expert's report—specifically regarding the Lack of Marketability Discount (DLOM)—shows that judges will take an active role in ensuring valuation reflects the commercial reality of the parties' relationship. The decision to remove the DLOM for a 50% stake while applying a heavy discount for a 0.0143% stake demonstrates a sophisticated understanding of how control (or the lack thereof) affects value.

Finally, the case has significant implications for nominee shareholding arrangements, which are common in Singapore and Malaysia for regulatory or tax reasons. It highlights the danger for the "silent" investor (the beneficiary) and the heavy burden on the "front" man (the trustee). The use of "Reserved Matters" in a Trust Deed is shown to be an effective shield, but only if the courts are willing to back those clauses with substantial equitable compensation when they are ignored. This judgment provides that backing, placing Eller v Cheong at the forefront of Singapore's trust law jurisprudence.

Practice Pointers

• Drafting Reserved Matters: When drafting trust deeds for nominee shareholdings, ensure that "Reserved Matters" are explicitly defined and include not just share issuances, but also mergers, disposals of assets, and changes to the constitution. This case confirms that such clauses provide the necessary framework for establishing a breach of trust.
• Valuation Methodology: Practitioners should ensure their valuation experts consider both the GPC and DCF methods where appropriate. The court in this case found the DCF method particularly useful for a growing company with clear sales projections.
• The DLOM Trap: Be wary of applying marketability discounts (DLOM) inconsistently. As shown here, a 50% stake in a two-person company may not warrant a DLOM if it represents joint control, whereas a tiny minority stake almost certainly does.
• Causation in Equity: When defending a quantum claim, the "but for" argument must be grounded in more than just the form of the transaction. The defendant failed here because the capital was already available as a loan; the breach (the issuance) didn't "create" the success.
• Expert Credibility: Ensure that expert reports are not only mathematically sound but also "logical and supported." An expert who ignores the earnings potential of a company in favor of a pure net asset value approach risks being disregarded entirely.
• Foreign Witnesses: If a key witness is in Malaysia and refuses to testify, rely on Section 32(1)(j)(iv) of the Evidence Act, but be prepared for the court to give the statement limited weight. Whenever possible, use the Singapore International Commercial Court (SICC) or other mechanisms to compel testimony if the jurisdiction allows.
• Equitable Compensation is Reparative: Always frame the claim as the difference between the counterfactual "no-breach" position and the actual position. Avoid conflating this with the recovery of specific assets unless a substitutive remedy is truly viable.

Subsequent Treatment

This judgment is the definitive word on quantum following the liability findings in [2020] SGHC 106. It has been cited in subsequent Singaporean discourse as a key example of the court's application of reparative equitable compensation and the "Value A minus Value B" framework. Its reliance on Butt v Kelson continues to be the standard for cases involving the misuse of trust-held voting rights in a corporate context.

Legislation Referenced

• Evidence Act (Cap 97, 1997 Rev Ed) s 32(1)(j)(iv)

Cases Cited

• Applied: Butt v Kelson [1952] 1 Ch 197
• Referred to: [2020] SGHC 106 (The Liability Trial)
• Referred to: [2021] SGHC 253 (The present judgment)

Source Documents

• Original judgment PDF: Download (PDF, hosted on Legal Wires CDN)
• Official eLitigation record: View on elitigation.sg